

Study of investigational cemiplimab in patients with **locally advanced or metastatic basal cell carcinoma and cutaneous squamous cell carcinoma**




Primary Objective: evaluate the safety and efficacy of cemiplimab in patients with locally advanced or metastatic BCC or CSCC in real-world clinical settings



PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BCC OR CSCC (N=287)

OPEN LABEL INTERVENTION



Primary Endpoints

Objective response rate^b
Disease control rate^b
Duration of response
Time to response
Progression-free survival

Overall survival
Time to treatment failure
Disease specific death^a
Safety



FIND OUT MORE

Scan here to find out more about this study at <https://clinicaltrials.gov/ct2/show/NCT03836105>

This information is intended for investigators interested in open clinical trials.

The use of cemiplimab described herein is investigational and has not been evaluated by any regulatory authority.

Please see full prescribing information in your country for cemiplimab.

^aPatients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions. ^bBased on investigator assessment.

BCC, basal cell carcinoma; CSCC, cutaneous squamous cell carcinoma; IV, intravenous; N, number of patients.

CEMPIPLIMAB

An Investigational, Fully Human PD-1 Monoclonal Antibody

Designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation¹

SELECTED INCLUSION CRITERIA^a



Eligible for treatment with and prescribed cemiplimab for advanced CSCC or advanced BCC

SELECTED EXCLUSION CRITERIA^a



Receiving cemiplimab for an indication other than advanced CSCC or advanced BCC



Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study



Patients concurrently participating in any study including administration of any investigational drug (including cemiplimab) or procedure (including survival follow up)



For more information, visit www.clinicaltrials.gov or please call [+353 (0)61 533 400 OR 844 REGN-MID].
NCT03836105
<https://clinicaltrials.gov/ct2/show/NCT03836105>

This information is intended for investigators interested in open clinical trials.

The use of cemiplimab described herein is investigational and has not been evaluated by any regulatory authority. Please see full prescribing information in your country for cemiplimab.

^aInclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on [clinicaltrials.gov](https://www.clinicaltrials.gov) for complete details.

BCC, basal cell carcinoma; CSCC, cutaneous squamous cell carcinoma; PD-1, programmed cell death protein-1.

Current per [clinicaltrials.gov](https://www.clinicaltrials.gov) as of October 30, 2023.

1. Markham A, Duggan S. *Drugs*. 2018;78(17):1841-1846.

CEM-EM-0025 November 2023.

©2023 Regeneron Pharmaceuticals, Inc. All rights reserved.